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Abstract Calprotectin is a calcium-binding cytosolic protein,
mainly expressed in immune cells, such as neutrophils, mono-
cytes, and macrophages. Our study aimed to evaluate the di-
agnostic value of calprotectin for adult-onset Still’s disease
(AOSD), by comparing serum calprotectin concentrations in
patients with AOSD (n=46), rheumatoid arthritis (RA, n=34),
primary Sjögren syndrome (pSS, n=40), systemic lupus ery-
thematosus (SLE, n=39), osteoarthritis (OA, n=20), and
healthy controls (HCs, n=49). Calprotectin concentrations
were significantly higher in patients with AOSD (55.26±
18.00 ng/ml), compared to patients with RA (39.17±
18.90 ng/ml), pSS (35.31±19.47 ng/ml), SLE (32.21±
25.01 ng/ml), OA (19.24±10.67 ng/ml), and HCs (8.46±
5.17 ng/ml). All the differences were highly significant
(p<0.001). Using receiver-operating characteristic curve, the
cut-off value of calprotectin was defined as 45.488 ng/ml, and
its sensitivity and specificity for AOSD diagnosis were 63.0
and 80.1 %, respectively. The positive rate of calprotectin was
significantly higher in AOSD cases compared to patients with
other diseases and healthy controls (p<0.001). Serum
calprotectin was positively correlated with ferritin (r=0.294,
p<0.05), and concentration of hemoglobin was significantly
lower in calprotectin-positive patients compared to negative
patients in AOSD (103.49±20.21 g/l vs 115.71±15.59 g/l, t=
−2.142, p=0.038). These findings suggest that serum
calprotectin may serve as a promisingmarker for the diagnosis
of AOSD and monitor disease activity to a certain extent.
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Introduction
Adult-onset Still’s disease (AOSD) is a systemic disease with
unclear etiology, characterized by spiking fever, arthritis, ev-
anescent rash, lymphadenopathy, hepato-splenomegaly, sore
throat, neutrophilic leukocytosis, and abnormality of liver en-
zymes [1]. Before the diagnosis of AOSD, infectious, neoplas-
tic, and other rheumatological disorders should be ruled out.
AOSD is self-limiting, but more than one third of patients
develop severe systematic damage with a poor prognosis [1,
2]. Since there were no disease-specific manifestations and
serologic markers, the diagnosis for AOSD and accurate de-
termination of disease activity is difficult [3, 4]. The currently
used markers for the diagnosis of AOSD included erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), and se-
rum ferritin, which lacking the sensitivity, specificity, and pre-
cision to diagnose AOSD and to monitor the disease activity.
Thus, specific serological marker for diagnosis and assess-
ment of disease activity in AOSD is urgently needed.
Calprotectin is a calcium-binding cytosolic protein that be-
longs to the S100 family, which presents in regenerative cells
such as neutrophils, monocytes, macrophages, epithelial, and
endothelial cells [5]. It is widely distributed in human tissues,
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body fluids, and cells. In neutrophils, calprotectin distributes
in the cytosol outside lysosomes and constitutes approximate-
ly 5 % of the total cellular proteins and is a marker for neu-
trophil’s update [6]. Calprotectin may involve modulation of
inflammatory and calcium-dependent regulation of protein
phosphorylation, transcription, and enzyme activities [7, 8].
Furthermore, previous studies have showed that calprotectin
was related to disease activity in several inflammatory dis-
eases, such as juvenile rheumatoid arthritis (JRA) [9–11], re-
active arthritis [12], acute gouty arthritis [13], and SLE [14].
In patients with RA, calprotectin was detected in the inflamed
synovial and has increased in plasma and synovial fluid from
affected joints, which proves it is strongly correlated with joint
inflammation and damage in RA [15]. Likewise, the concen-
trations of calprotectin were also elevated in intestinal muco-
sa, serum, and feces in patients with Crohn’s disease and ul-
cerative colitis [16, 17]. One publication reported that the
expression levels of serum calprotectin were elevated in pa-
tients with AOSD and correlated with disease activity and
severity but with the comparison between AOSD cases and
healthy controls only [18].
Our study aimed to evaluate the diagnostic value of
calprotectin for AOSD, by comparing the serum levels of
calprotectin in AOSD patients with several other autoimmune
disease controls, i.e., rheumatoid arthritis (RA), primary
Sjögren syndrome (pSS), systemic lupus erythematosus
(SLE), osteoarthritis (OA), as well as with healthy controls
(HCs). The correlation between calprotectin and disease
activity/severity was also analyzed at the same time. Our re-
sults indicate that calprotectin could be a promising marker for




Serum samples were collected from 46 patients with AOSD,
34 patients with RA, 40 patients with pSS, 39 patients with
SLE, 29 patients with OA, and 49 HCs. The AOSD patients
fulfilled the criteria for a diagnosis of AOSD, with the exclu-
sion of patients who had infections, hematological, and other
autoimmune diseases [19]. Patients suffering from other auto-
immune diseases were selected according to the disease-
specific diagnostic criteria [20–23]. Patients with either dis-
ease were selected without development of other rheumatic
diseases. All the patients were recruited from the Department
of Rheumatology and Immunology at Peking University Peo-
ple’s Hospital. The patients were not subject to medical treat-
ment at the time of serum samples obtained. The 49 non-
related healthy controls were recruited from Health Care
Centers from Peking University People’s Hospital and were
selected without any disease records.
All sera were kept at −20 °C. The baseline demographic
characteristics of patients and controls are shown in Table 1.
This study was approved by the ethics committee of Peking
University People’s Hospital, and informed consent was re-
ceived from all study subjects.
Clinical and laboratory assessment
Clinical features of AOSD patients, including fever, evanes-
cent rash, sore throat, arthritis, serositis, hepatomegaly,
splenomegaly, and lymphadenopathy were recorded. Com-
plete blood cell count, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), serum ferritin, glutamic pyruvic
transaminase (ALT), and glutamic oxalacetic transaminase
(AST) and serum levels of IgG, IgA, and IgM were detected.
Measurement of calprotectin concentrations
Serum concentrations of calprotectin were measured using
commercial ELISA kits (Sun Biomedical Technology Co.,
Ltd, Beijing, China) according to the manufacturer’s protocol.
Each 100 μl sample of serum or standard was placed in a
microtiter plate well coated with a monoclonal antibody to
human calprotectin heterodimer. After incubation for 1 h at
room temperature, the wells were washed four times with
buffer, and samples were labeled with 100 μl of dilute tracer
(biotinylated secondary antibody to human calprotectin). Af-
ter washing again, each well received 100 μl of diluted
streptavidin-peroxidase conjugate, which reacts specifically
with the calprotectin-bound tracer. After incubation at room
temperature for 1 h, excess conjugate was removed by wash-
ing, and tetramethylbenzidine substrate solution (100 μl) was
applied to each well for 30 min in the dark at room tempera-
ture. To terminate the reaction, stop solution containing citric
acid (100 μl) was added to each well, and absorbance was
measured at 450 nm using an ELISA plate reader (Bio-Rad,
CA, USA). The coefficient of variation was <6 % for dupli-
cate measurements by ELISA.
Statistical analysis
The Statistical Package for Social Sciences version 16.0
(SPSS, Chicago, IL, USA) was used to analyze the data. Re-
sults are shown as mean±SD. The results were analyzed by
independent t tests, Mann–Whitney U test, and chi-square
tests as appropriate. The ability of calprotectin to diagnose
AOSD was evaluated by a receiver-operating characteristics
(ROC) curve analysis. The correlations between serum
calprotectin level and disease-related variables were evaluated
with Pearson or Spearman’s correlation test. A p value <0.05
was regarded as statistically significant.
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Results
Clinical characteristics of the AOSD patients
In AOSD patients, the main clinical symptoms include fever
(100%), evanescent rash (73.9 %), arthritis (50%), sore throat
(71.7 %), serositis (26.1 %), hepatomegaly (28.2 %), spleno-
megaly (50 %), and lymphadenopathy (50 %). The general
and clinical characteristics are summarized in Tables 1 and 2,
respectively.
Sensitivity and specificity of calprotectin in diagnosis
of AOSD
As shown in Fig. 1a, mean levels of calprotectin were
significantly higher in patients with AOSD (55.26±
18.0 ng/ml), RA (39.17±18.90 ng/ml), pSS (35.31±
19.47 ng/ml), SLE (32.21±25.01 ng/ml), OA (19.24±
10.67 ng/ml), compared to HCs (8.46±5.17 ng/ml); all
the differences were statistically significant (p<0.001).
Furthermore, calprotectin levels were significantly higher
in patients with AOSD than in patients with other autoim-
mune diseases those mentioned above (p<0.001, Fig. 1a).
Using ROC curve, the calculated cut-off value of
calprotectin was 45.488 ng/ml. With the cut-off value, the
positive rate of calprotectin in patients with AOSD (29/46,
63.0 %) was significantly higher than those in patients with
other rheumatic diseases, including RA (11/34, 32.4 %),
pSS (15/40, 37.5 %), SLE (12/39, 30.8 %), OA (0/29,
0 %), as well as HCs (0/49, 0 %) (p<0.001, Fig. 1b). The
sensitivity and specificity of serum calprotectin were 63.0
and 80.1 % for AOSD, respectively. The positive and neg-
ative predictive values of the calprotectin in AOSD were
43.3 and 90.0 %. Thus, the calprotectin would be consid-
ered to be Bgood^ or Bfair^ at separating AOSD patients
from individuals with other rheumatic diseases and health
controls.
Associations of serum calprotectin levels with serologic
parameters in AOSD
Next, we evaluated whether a positive test of serum
calprotectin could be correlated to other serologic param-
eters in AOSD. As shown in Table 3, the levels of serum
calprotectin were significantly correlated with serum fer-
ritin in AOSD (r=0.294, p=0.048). The level of hemo-
globin (Hb) was significantly lower in serum calprotectin-
positive patients (103.49±20.21 g/l), compared to serum
calprotectin negative patients (115.71±15.59 g/l), (t=
−2.142, p=0.038). The concentration of ESR and CRP
were elevated in calprotectin-positive patients, as com-
pared to negative patients, (ESR: 79.14±34.98 mm/h vs
60.24±33.23 mm/h, p=0.077. CRP: 100.78±58.90 mg/l
vs 68.78±56.02 mg/l, p=0.076), though being unable to
reach the statistical significance. There was no significant
difference in white blood cell (WBC), blood platelet
(PLT), ALT, AST, IgG, IgA, and IgM between the two
groups (p>0.05) (Table 4).
Table 2 Clinical characteristics of AOSD patients
Clinical manifestations N (%) Annotation
Fever 46 (100) In the course of disease, the temperature in all patients were fluctuate from 35.95±0.34 °C to 39.74±0.61 °C
Evanescent rash 34 (73.9) Often appear with fever, the rash is transient, dissipate with defervescence
Sore throat 33 (71.7) Patients’ complaint
Arthritis 23 (50) Mainly showed by joint tenderness and pain, swelling is rare
Serositis 12 (26.1) Demonstrated by radiography
Hepatomegaly 13 (28.2) Demonstrated by radiography
Splenomegaly 23 (50) Demonstrated by radiography
Lymphadenopathy 23 (50) Demonstrated by radiography and physical examination
Table 1 General characteristics of patients and controls. All values presented as number or mean±SD
AOSD RA pSS SLE OA HC
N 46 34 40 39 29 49
Age (years, mean±SD) 36.6±17.5 56.9±9.9 55.4±12.2 40.0±15.4 56.6±7.1 35.6±9.7
Female/male 23/23 27/7 34/6 29/10 25/4 23/26
Disease duration (years, mean±SD) 1.3±1.8 8.6±6.9 11.4±10.3 6.0±5.9 7.8±6.9
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Correlation between serum calprotectin levels and clinical
manifestations in AOSD
Serum calprotectin in AOSD patients showed no correlation
with their age and gender (p>0.05). Except the proportion of
patients with sore throat was higher in calprotectin negative
group than the positive group (p=0.017), there was no signif-
icant difference between the two groups in other clinical fea-
tures including fever, evanescent rash, arthritis, serositis,
hepatomegaly, splenomegaly, and lymphadenopathy
(p>0.05, Table 5).
Discussion
AOSD is a systemic disease of unknown etiology. Although it
is self-limiting, more than one third of patients develop severe
systematic damage with a poor prognosis [2]. The diagnostic
spectrum of AOSD is wide but lacking the disease-specific
manifestations and serologic markers for accurate diagnosis
of AOSD and assess of disease activity and severity [3, 4].
Former studies have shown follistatin-like protein 1 could be a
useful biomarker for systemic JIA activity [24], but it failed to
present its use for disease activity in AOSD [25]. Although
previous studies have proposed IL-18 [26, 27], serum soluble
intracellular adhesion molecule-1 (sICAM-1) [2], and macro-
phage migration inhibitory factor (MIF) [28] for AOSD activ-
ity and/or severity, there were many limitations for these
markers to put into clinical utility. Serum ferritin is the most
frequently used laboratory index for AOSD diagnosis and
activity [1], but it can also increase during a non-specific in-
flammation and may be affected by iron concentration in the
body. ESR and CRP are also used for evaluation of AOSD
activity, but they are so common in inflammation or no-
inflammation diseases, thus lacking specificity for AOSD.
Calprotectin which is supposed to be involved in the recruit-
ment of inflammatory cells to sites has been deemed to form
Bdamage-associated molecular patterns^ of injury [29, 30]. It
has been confirmed to exert an influence in several inflamma-
tory diseases such as JRA, reactive arthritis, acute gouty ar-
thritis, and SLE [9–14]. In patients with systemic-onset JRA,
calprotectin was highly expressed in patients with active
Table 3 The correlation
of calprotectin and
disease-related
laboratory data in AOSD













ESR erythrocyte sedimentation rate, CRP
C-reactive protein, WBC white blood cell,
Hb hemoglobin, PLT platelet, ALT
glutamic pyruvic transaminase, AST
glutamic oxalacetic transaminase
Fig. 1 a Calprotectin levels in AOSD patients and controls. Each dot
represents an individual serum. Bars display median and dotted line
represents cut-off values 45.488. Mean calprotectin levels were
significantly higher in patients with AOSD (55.26±18.0 ng/ml), RA
(39.17±18.90 ng/ml), pSS (35.31±19.47 ng/ml), SLE (32.21±
25.01 ng/ml), OA (19.24±10.67 ng/ml) than in HC (8.46±5.17 ng/ml)
(p<0.001). Calprotectin levels were significantly higher in patients with
AOSD than in patients with RA, pSS, SLE, OA, and HC (p<0.001). b
The positive rate of calprotectin in patients with AOSD and controls. The
positive rate of calprotectin in patients with AOSD (63.0 %, 29/46) were
significantly higher than those in patients with RA (32.4 %, 11/34), pSS
(37.5 %, 15/40), SLE (30.8 %, 12/39), OA (0 %, 0/29), HC (0 %, 0/49)
(p<0.001). ***p<0.001
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disease and made them good candidates as markers for the
diagnosis of systemic-onset JIA and monitoring disease activ-
ity [10, 11]. In patients with RA, calprotectin has been proved
to possess strong correlation with joint inflammation and dam-
age [15]. Results from 42 patients with polymyalgia
rheumatica or temporal arteritis showed that serum
calprotectin levels are highly correlated with the acute phase
clinical manifestations of the disease and its related parame-
ters such as ESR, CRP, etc., and calprotectin levels were sig-
nificantly decreased after the treatment with glucocorticoids
[31]. These findings suggest that serum calprotectin levels can
provide reliable clinical indicators for monitoring disease ac-
tivity and severity of rheumatic diseases.
Although one study has shown that serum calprotectin in-
creased in patients with AOSD and was closely related with
disease activity and severity, the work merely compared the
serum calprotectin concentrations between AOSD patients
and healthy individuals [18]. To better evaluate the value of
calprotectin for AOSD diagnosis, in present work, we not only
included healthy individuals as controls but also utilized sev-
eral disease controls to discriminate AOSD from other rheu-
matic diseases. Our data indicate that serum calprotectin levels
were significantly elevated in patients with AOSD, RA, pSS,
SLE, and OA than HCs. Furthermore, calprotectin levels were
significantly higher in patients with AOSD than in patients
with other rheumatic diseases mentioned above. These data
may help us to distinguish AOSD from a number of rheumatic
diseases with frequent manifestation of arthritis.
Using ROC curve, the cut-off value of calprotectin was
defined as 45.488 ng/ml, with a sensitivity and specificity
being 63.0 and 80.1 %, respectively. Serum calprotectin in
patients with AOSD showed no obvious relevance to their
age and gender as well as the patient’s fever, evanescent rash,
arthritis, serositis, hepatomegaly, splenomegaly, and lymph-
adenopathy. However, our data showed that the proportion
of patients with sore throat was higher in calprotectin negative
group than the positive group, which has not been reported
before. In a review of 341 AOSD cases, the incidence of sore
Table 5 The correlation of
calprotectin and clinical
manifestations in AOSD
Clinical features Calprotectin-positive (n=29) Calprotectin-negative (n=17) χ2 p-
values
n % n %
Fever 29 100 17 100 3.695 0.055
Evanescent rash 21 72.4 13 76.5 0 1
Sore throat 18 62.1 15 88.2 5.698 0.017
Arthritis 14 48.3 9 52.9 0.093 0.760
Serositis 10 34.5 2 11.8 1.811 0.178
Hepatomegaly 10 34.5 3 17.6 0.783 0.376
Splenomegaly 16 55.2 7 41.2 2.339 0.126
Lymphadenopathy 15 51.7 8 47.1 0.093 0.760
Table 4 Divided AOSD patients
into calprotectin-positive and
calprotectin-negative groups by
the calprotectin cut-off value, the
comparison of laboratory data
between the two groups
Laboratory data Calprotectin-positive (n=29) Calprotectin-negative (n=17) p-
values
Ferritin (ng/ml) 1536.20±647.53 1300.80±686.18 0.250
ESR (mm/h) 79.14±34.98 60.24±33.23 0.077
CRP (mg/l) 100.78±58.90 68.78±56.02 0.076
WBC (10^9/l) 17.89±4.69 16.24±5.40 0.284
Hb (g/l) 103.49±20.21 115.71±15.59 0.038
PLT (10^9/l) 336.91±162.68 334.24±63.77 0.949
ALT (U/l) 106.48±169.69 141.29±194.95 0.528
AST (U/l) 93.83±163.84 76.06±118.58 0.698
IgG (g/l) 12.02±5.61 13.05±2.84 0.484
IgA (g/l) 4.18±4.54 3.07±1.28 0.224
IgM (g/l) 1.50±0.82 1.36±0.79 0.563
ESR erythrocyte sedimentation rate, CRP C-reactive protein, WBC white blood cell, Hb hemoglobin, PLT
platelet, ALT glutamic pyruvic transaminase, AST glutamic oxalacetic transaminase
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throat was reported to be 69 % and was particularly displayed
prevalent in the first month of disease course [32]. In our
study, the incidence of sore throat in AOSD is 71.7 %, which
is consistent with previous studies. At present, we are unable
to give a clear explanation for the higher incidence of sore
throat in calprotectin negative patients, but we assume that it
could be duo to the appearance of sore throat and the increase
of calprotectin occurred at different stages of the diseases.
Further functional studies will hopefully elucidate the role of
calprotectin involved in the manifestation in the future. Re-
garding serologic parameters, serum calprotectin had strong
correlation with serum ferritin in AOSD patients, which has
been reported previously [18]. Interestingly, our data indicated
that serum calprotectin was negatively correlated with Hb in
AOSD patients. The patients who were positive for
calprotectin had lower Hb content. This funding agrees with
the characteristics of anemia in chronic inflammatory disease
and the anemia in AOSD has also been reported in previous
studies [4]. The anemia condition can be remitted during the
disease’s asymptomatic periods and can also return during its
exacerbations [33]. Meanwhile, our data showed that the
levels of ESR and CRP were higher in serum calprotectin-
positive patients than in negatives, suggesting that calprotectin
together with these two inflammatory markers may provide
messages for disease activity. Previously, Jung SY et al. re-
ported that serum calprotectin has strong correlations with
WBC, CRP, AST, but not with ESR, Hb, or PLT [18]. In our
study, there were no associations between calprotectin and
WBC, PLT, ALT/AST, IgG, IgA, and IgM. This may be ex-
plained by the divergence of the study case numbers between
ours (n=46) and Jung’s work (n=25).
In conclusion, serum calprotectin levels were significantly
increased in AOSD and it is correlated with serum ferritin and
Hb. It can be a promising marker for AOSD diagnosis and mon-
itoring disease activity to a certain extent. The limitation of this
study is the modest sample size. A prospective study with larger
numbers of cases and a close follow-up of patients are needed to
reveal the expression changes of calprotectin that accompany
disease activation, remission, and treatment more precisely.
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